Meeting
Plenary Presentations
Abstract Number: Plenary
SHM Converge 2021
Background: Antibiotics targeted against C. difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biologically-derived microbiome therapeutic of purified Firmicute spores for treatment of recurrent CDI. Methods: Adults ≥18 years with recurrent […]
Abstract Number: L10
SHM Converge 2022
Background: Clostridioides difficile infection (CDI) is a leading healthcare-associated infection causing debilitating diarrhea, life-threatening complications, 20,500 deaths and healthcare costs of up to $5.4 billion annually in the US. The main driver of CDI costs is hospitalizations, and patients with higher CDI recurrence rates have more hospitalizations and emergency department visits and longer hospital stays. […]
Plenary Presentations
Abstract Number: Plenary
SHM Converge 2021
Background: Antibiotics targeted against C. difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biologically-derived microbiome therapeutic of purified Firmicute spores for treatment of recurrent CDI. Methods: Adults ≥18 years with recurrent […]